R&D field
Unike Biotech focuses on the field of chronic metabolic diseases, guided by unmet clinical needs, and uses its independent core technology platform to develop innovative recombinant protein drugs and biosimilars, providing patients with more effective, safer, and accessible treatment options.
Diabetes
Focus on type 2 diabetes and its complications, develop long-term GLP-1 receptor agonists, insulin analogues and other innovative drugs, and improve patients' blood sugar control and medication compliance.
Obesity
In response to the global trend of obesity, develop multi-target metabolic regulatory protein drugs to achieve safe and effective weight management through appetite regulation and energy metabolism intervention.
Non alcoholic steatohepatitis(NASH)
Developing innovative recombinant protein drugs targeting liver metabolism and inflammatory pathways to prevent disease progression in response to the current lack of effective therapeutic drugs for NASH.
Metabolic syndrome
Developing a multi effect fusion protein drug that covers metabolic abnormalities such as hyperlipidemia, hypertension, and hyperuricemia, to achieve comprehensive management of metabolic syndrome.
Growth and developmental disorders
Develop long-acting growth hormone analogs and fusion proteins to reduce injection frequency and improve treatment compliance in children and adults with growth hormone deficiency.
Biosimilars
Discover high-quality biosimilars of heavyweight biopharmaceuticals already on the market, reduce production costs through process innovation, and improve patient access to medication.
Market opportunity
Chronic metabolic diseases have become a major global public health challenge. According to statistics, there are more than 500 million patients with diabetes, more than 1 billion obese people and more than 300 million NASH patients worldwide, and the incidence rate continues to rise. The existing treatment methods still have problems such as limited efficacy, significant side effects, inconvenient medication, and poor accessibility, and clinical needs are far from being met.
Unike Biotech, with its four core technology platforms, has formed differentiated advantages in long-acting, oral administration, and fusion proteins, and is expected to develop innovative metabolic disease drugs with international competitiveness, benefiting patients worldwide.